MAXCYTE, INC. — Form SCHEDULE 13D
Filed October 15, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Liontrust Investment Partners LLP, a UK-based investment firm, filed a Schedule 13D with the SEC on October 15, 2026, indicating acquisition of beneficial ownership in MaxCyte, Inc. (a $230.7M market-cap biotech company). The filing document references MaxCyte's Rockville, MD headquarters and Liontrust's London office address, but the specific share count, percentage ownership stake, and acquisition date are not disclosed in the provided filing header text.
Why this rating
Schedule 13D filing alone is routine disclosure; significance depends on undisclosed ownership %. If <5%, largely administrative. Requires full document review for material threshold assessment.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.